Adult Dosing

Vitiligo

• Apply qwk or prn to well-defined, depigmented areas only and that area should be exposed to suitable source of UVA

Pediatric Dosing

• Note: Safety and effectiveness in pediatric patients <12 yrs of age have not been established

Vitiligo

• Children >12 yrs: Apply qwk or prn to well-defined, depigmented areas only and that area should be exposed to suitable source of UVA

• As a topical re-pigmenting agent in vitiligo in conjunction with controlled doses of ultraviolet A (320-400 nm) or sunlight

• Hypersensitivity to any of the ingredients of the product
• Idiosyncratic reactions to psoralen compounds or a history of sensitivity reactions to them
• Melanoma or with a history of melanoma
• Invasive skin carcinoma
• Photosensitivity diseases such as porphyria, acute lupus erythematosus, xeroderma pigmentosum
• Children <12 years of age

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• It should be applied only by a physician under controlled light exposure and subsequent light shielding because it is a potent drug and may produce severe burns if improperly used. This preparation should never be dispensed to a patient
• Application should be limited to small well-defined lesions and is preferable on lesions that can be protected from subsequent exposure to radiant UVA
• Serious burns from either UVA or sunlight (even through window glass) can result if the recommended dosage of the drug and exposure schedules are not maintained and/or protective covering and sunblocks are not used
• Patients who subsequently have oral psoralen – UVA treatment (PUVA) are at increased risk for developing skin cancer. Caution should be exercised in patients who have fair skin, a history of prior coal tar UV treatment, or had ionizing radiation or taken arsenical compound

Cautions: Use cautiously in

• Concomitant therapy with known photosensitizing agents
• History of prior coal tar UV treatment
• Patient with fair-skinned

Oxsoralen interacts with :

	Afinitor
	Astagraf XL
	Cyclosporine
	Everolimus
	Gengraf
	Hecoria
	Neoral
	Prograf
	Protopic
	Rapamune
	Restasis
	Sandimmune
	Sirolimus
	Tacrolimus

Pregnancy Category:C

Breastfeeding: Safety unknown; manufacturer advises caution.

• DERM: Severe burns, blistering, burns
• HYPERSENSITIVITY: Photosensitivity, phototoxicity
• MISC: Secondary malignancy

• Photosensitizing agents; upon photoactivation, conjugates and forms covalent bonds with DNA which leads to the formation of both monofunctional and bifunctional adducts
• Extensively metabolized in the liver; CYP450: 1A2, 2A6 potent inhibitor
• Renally excreted: 95%
• Half-life: 2 hrs

US Trade Name(s)

• Oxsoralen

US Availability

Oxsoralen

• LOTN: 1%

Canadian Trade Name(s)

• Oxsoralen

Canadian Availability

Oxsoralen

• LOTN: 1%

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Dermatologic

Dermatologic Topical Agents

Photosensitizing Agents